Rodney Pearlman, Ph.D.


Rodney Pearlman, Ph.D. is the President of The Bluefield Project to Cure Frontotemporal Dementia. Prior to joining The Bluefield Project, Dr. Pearlman served as the CEO of Bay Area start-ups Saegis Pharmaceuticals, Nuon Therapeutics and InCarda Therapeutics. At Saegis, which he also co-founded, Dr. Pearlman developed drug candidates to improve memory and cognition for a variety of indications, including Alzheimer’s disease and schizophrenia. Under Dr. Pearlman’s management, Saegis was acquired by Danish neuropharmaceutical powerhouse Lundbeck. Prior to co-founding Saegis, Dr. Pearlman held leadership positions at Valentis and Genentech and was on the faculty at the University of Texas, Austin.

Dr. Pearlman holds a B. Pharm from Monash University in Melbourne, AU and a Ph.D. in pharmaceutical chemistry from the University of Kansas. He has two adult children and he and his wife live in El Granada, CA.


Chief Business Officer

Christine Siu is the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia. Previously, she was the first employee at Global Blood Therapeutics, where she incubated the company with Third Rock Ventures and grew the company from drug discovery to IND-enabling studies for the lead drug to treat sickle cell disease. Prior to Global Blood Therapeutics, Ms. Siu was an investor at Third Rock Ventures, Thomas, McNerney & Partners and Warburg Pincus, where she invested over $400M in early stage, growth equity, public investments, and leveraged buyouts in the life sciences and health care sectors. Ms. Siu is also the chief operating officer of Eidos Therapeutics, a company started by BridgeBio to treat diseases associated with transthyretin amyloidosis. Ms. Siu holds a B.S. with distinction in cellular molecular biology and economics from the University of Michigan and a M.B.A. from Harvard Business School. She lives in San Mateo, CA with her husband and sons.

Laura Mitic, Ph.D.

Director of Translational Research

Laura Mitic, Ph.D. is the Director of Translational Research at the Bluefield Project to Cure Frontotemporal Dementia.  Dr. Mitic holds a B.A. from Northwestern University, a Ph.D. in cell biology from Yale University and completed postdoctoral studies at the University of California, San Francisco. She and her husband live in San Francisco, CA with their two children.

Alexandra Nicholson, PH.D.

Associate Director, Research Partnerships

Alexandra (Andra) Nicholson is the Associate Director of Research Partnerships at the Bluefield Project to Cure Frontotemporal Dementia. Prior to joining the Bluefield Project, Dr. Nicholson received a B.S. in biochemistry from Beloit College, as well as a Ph.D. in cellular neuroscience from Northwestern University where she studied the molecular mechanisms of Alzheimer's disease. After completing her Ph.D., Dr. Nicholson continued in academic research at Mayo Clinic Jacksonville investigating the genetic and cellular contributions to frontotemporal lobar degeneration. Dr. Nicholson resides in Jacksonville, FL where she lives with her husband and two step-children.